1[1]Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to Gefinitib therapy[DB/OL]. Science, 29 April 2004 [Dol: 10. 1126/science.1099314].
2[3]Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
3[4]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oneol, 2003,21: 2237-2246.
4[5]Kris MG, Natale RS, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor tyrosine kinase,in symptomatic patients with non-small-cell lung cancer: a randomized trial [J]. JAMA, 2003,290:2149-2158.
5[6]Simon GR, Ruckdeschel JC, Williams C, et al. Gefitinib(ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution [J ]. Cancer Control,2003,10(5) :388-395.
6[7]Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with Gefitinib (ZD1839, ‘Iressa') on an expanded access study [J].Lung Cancer, 2004,44 (2): 221-230.
2Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839 for patients with advanced non-small cell lung cancer (IDEAL- 1 ) [ J ]. Proc Am Soc Clin Oncol, 2002, 21:1188a
3Kris M, Natale R, Herbst R, et al. A phase Ⅱ trial of ZD1839 in advanced NSCLC patients who had failed platinum and docetaxel based regimens (IDEAL-2) [J]. Proc Am Soc Clin Onco, 2002,21: 1166a
4Giaccone G, Johnson D H, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1 ) [J]. Ann Oncol, 2002, 13(Suppl. 5): 2a
5Johnson D H, Herbst R, Giaccone G, et al. ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC):Results from a phase Ⅲ clinical trial (INTACT 2) [J] . Ann Oncol, 2002, 13 (Suppl. 5): 127a
6Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J] . Clin Cancer Res, 2000, 6(5):2053 - 2063
